Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor
FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

June 15, 2020 — The U.S. Food and Drug Administration (FDA) today revoked the emergency use authorization (EUA) that ...

Home June 15, 2020
Home
Videos | Coronavirus (COVID-19)
VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine and Azithromycin

Interview with Andrew D. Krahn, M.D.,FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

Home May 28, 2020
Home
WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19. #COVID19 #SARScov2 #Hydroxychloroquine
Feature | Coronavirus (COVID-19)
WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine and ...

Home May 27, 2020
Home
Videos | Coronavirus (COVID-19)
VIDEO: Overview of Hydroxychloroquine and FDA Warning in its use to Treat COVID-19

Marianne Pop, Pharm.D., BCPS, a clinical pharmacist and clinical assistant professor with the regional pharmacy program ...

Home May 18, 2020
Home
Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell
News | Pharmaceuticals
Icosapent Ethyl Significantly Reduces Revascularizations in Statin Patients

May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy ...

Home May 17, 2020
Home
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020
News | Stents
TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI

May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) ...

Home May 17, 2020
Home
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia 

May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating ...

Home May 13, 2020
Home
There have been several safety reports to the FDA that COVID-19 patients receiving hydroxychloroquine and chloroquine, either aloneaths and Injuries From Use of Antimalarial Drugs in COVID-19 Patients. he U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors there are serious side effects when using hydroxychloroquine and chloroquine in the off-lable use to treat COVID-19 patients. This includes potentially life-threatening heart rhythms. #COVID19 #SARScov2
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor
FDA Reports of Deaths and Injuries From Use of Antimalarial hydroxychloroquine in COVID-19 Patients

April 23, 2020 — The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors ...

Home April 24, 2020
Home
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | Dave Fornell, Editor
ACC 2020 Late-breaking Presentations

Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC ...

Home April 09, 2020
Home
ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM
News | Coronavirus (COVID-19)
No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether ...

Home April 08, 2020
Home
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure
Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

Home March 29, 2020
Home
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020
News | Pharmaceuticals | Dave Fornell, Editor
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

Home March 28, 2020
Home
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

Home March 28, 2020
Home
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020
News | Antiplatelet and Anticoagulation Therapies
Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half 

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

Home March 28, 2020
Home
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20
News | Peripheral Artery Disease (PAD)
Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention 

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

Home March 28, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now